Evidence map›Paper›PMID 40963672›Full record

ArticleFrontiers in pharmacology2025

Population pharmacokinetic modeling of dexmedetomidine nasal spray in Chinese adults.

Yuanyuan Huang, Sheng Xu, Nassim Djebli, Hao Jiang, Guoping Yang

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuanyuan Huang *Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.
Sheng Xu *Jiangsu Hengrui Pharmaceuticals Co. Ltd., Lianyungang, China.
Nassim DjebliJiangsu Hengrui Pharmaceuticals Co. Ltd., Lianyungang, China.
Hao JiangJiangsu Hengrui Pharmaceuticals Co. Ltd., Lianyungang, China.
Guoping YangXiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The main objective was to build and qualify a population pharmacokinetic (PopPK) model for dexmedetomidine nasal spray in Chinese adults and explore the covariates affecting the PopPK model parameters. Methods: A population pharmacokinetic model was developed based on the results of 1,225 blood concentration points from 196 healthy volunteers (HV) and patients in phase I and phase III studies. Covariates significantly affecting pharmacokinetic characteristics were analyzed. Model selection was performed using nonlinear mixed-effects modeling (NONMEM), and covariates' screening was conducted using the traditional stepwise forward inclusion and backward elimination methods. Bootstrap and pcVPC methods were used for model validation. Logistic regression modeling was used to analyze the relationship between the C Results: The final model was a two-compartment model with first-order absorption and linear elimination. Inter-individual variability terms were estimated on clearance and absorption rate constant. The residual variability was described using combined proportional and additive error models. In the final model, body weight was included via theory-based allometric scaling (i.e., exponents of 0.75 for clearances and 1.0 for volumes of distribution). The absorption rate in the patients from phase III study was approximately 49% of that in the HV from phase I study. The estimated population typical values for CL, V2, Q, Vp, KA, F1, and ALAG in the final model were 35.3 L/h, 21.5 L, 116 L/h, 86.5 L, 0.523 h Conclusion: The present analysis successfully established a PopPK model for dexmedetomidine nasal spray in Chinese adults, confirming that body weight influences distribution and clearance. This PopPK model is being further explored to support pediatric dose recommendation.

Indexed as

dexmedetomidinemodel validationnasal sprayNONMEMpopulation pharmacokinetics

Identifiers

PMID40963672
PMCPMC12436384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.